MYSZ vs FIGS vs REAL vs CURV vs XERS

For growth investors, Xeris Biopharma Holdings, Inc.

(XERS) is the stronger pick with 43. 7% revenue growth year-over-year, versus -9. 4% for Torrid Holdings Inc. (CURV). FIGS, Inc. (FIGS) offers the better valuation at 80. 9x trailing P/E (65. 0x forward), making it the more compelling value choice. Analysts rate FIGS, Inc. (FIGS) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, FIGS, Inc.

(FIGS) is the cheapest at 80. 9x versus Xeris Biopharma Holdings, Inc. at 2071. 9x. On forward P/E, Xeris Biopharma Holdings, Inc. is actually cheaper at 55. 3x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Xeris Biopharma Holdings, Inc.

(XERS) delivered a total return of +104. 0%, compared to -99. 8% for My Size, Inc. (MYSZ). Over 10 years, the gap is even starker: FIGS returned -48. 8% versus MYSZ's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Torrid Holdings Inc.

(CURV) is the lower-risk stock at 0. 46β versus The RealReal, Inc. 's 2. 95β — meaning REAL is approximately 547% more volatile than CURV relative to the S&P 500. On balance sheet safety, My Size, Inc. (MYSZ) carries a lower debt/equity ratio of 4% versus 3% for Xeris Biopharma Holdings, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Xeris Biopharma Holdings, Inc.

(XERS) is pulling ahead at 43. 7% versus -9. 4% for Torrid Holdings Inc. (CURV). On earnings-per-share growth, the picture is similar: FIGS, Inc. grew EPS 1158% year-over-year, compared to -146. 7% for Torrid Holdings Inc.. Over a 3-year CAGR, MYSZ leads at 298. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

FIGS, Inc.

(FIGS) is the more profitable company, earning 5. 4% net margin versus -48. 4% for My Size, Inc. — meaning it keeps 5. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XERS leads at 8. 5% versus -47. 8% for MYSZ. At the gross margin level — before operating expenses — XERS leads at 81. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Xeris Biopharma Holdings, Inc.

(XERS) trades at 55. 3x forward P/E versus 307. 7x for The RealReal, Inc. — 252. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for REAL: 46. 5% to $18. 17.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Torrid Holdings Inc.

(CURV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 46)). The RealReal, Inc. (REAL) carries a higher beta of 2. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CURV: -93. 7%, REAL: -57. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MYSZ (Technology) and FIGS (Consumer Cyclical) and REAL (Consumer Cyclical) and CURV (Consumer Cyclical) and XERS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MYSZ is a small-cap high-growth stock; FIGS is a small-cap quality compounder stock; REAL is a small-cap high-growth stock; CURV is a small-cap quality compounder stock; XERS is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.